gms | German Medical Science

Introduction: Fatigue is an important aspect of PsA for patients (pts). Understanding the impact of fatigue on disease activity and patien- reported outcomes (PROs) is important for effective management of PsA. Aim: to study fatigue severity pts who report fatigue and those who do not, and to describe the prevalence of fatigue in PsA pts.

Methods: 187 (M/F=97 (50.2%)/90(48.8%) PsA pts fulfilling the CASPAR criteria were included. All pts underwent standard clinical examinations and PROs: quality of life (EQ5D and PsAID-12), work productivity (WPAI), and disability (HAQ). Pts reported fatigue by PsAID12 domain scale (0-10 score, grouped for analysis as 0 – no fatigue, 1-3 – low fatigue, 4-7 – moderate fatigue, >7 – severe fatigue). Patients were compared according to grouped fatigue scores using parametric tests and non-parametric tests. All p<0.05 were considered to indicate statistical significance.

Results: According to the results of the patients were identified: no fatigue - 26 (13.9%), low fatigue – 74 (39.5%), moderate fatigue – 51(27.2%) and severe fatigue – 38 (20.3%). When assessing the effect of fatigue on disease activity, it was found that patients with low, moderate and significant fatigue DAPSA is higher than in patients not experiencing fatigue (Table 1 [Tab. 1]) (for all p<0.0001). The groups of patients were comparable in terms of gender, age and biological therapy, as well as skin lesions. Also, in patients, depending on the severity of fatigue, scores reported worse outcomes in terms of quality of life, work impairment, and disability than those with lower fatigue scores (for all p<0.0001).

Conclusion: In PsA pts severe fatigue associated with to have worse disease activity, quality of life, work productivity and disability outcomes than those with no fatigue.

Disclosures: None declared